

Minutes of the
Extraordinary General Meeting

of

AFFIMED N.V.

held on Thursday, 10 October 2024

at:

the offices of De Brauw Blackstone Westbroek N.V.,
Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands

Minutes of the extraordinary general meeting (the "**EGM**") of Affimed N.V. (the "**Company**") held on 10 October 2024 at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.

Agenda item 1: Opening

Dr. Thomas Hecht, chairman of the Company's supervisory board (the "**Supervisory Board**") and chairman of the EGM (the "**Chairman**"), opened the EGM at 13:00 hours (CET) and welcomed those present.

Dr. Shawn Leland, whose proposed appointment as a member of the Company's management board (the "**Management Board**") was on the agenda of the EGM, introduced himself. Thereafter the Chairman noted that Mr. Reinier Kleipool, the Company's Dutch legal counsel, was appointed by the Chairman as secretary of the EGM.

The Chairman noted that on 12 September 2024, the record date for the EGM, the total issued share capital of the Company amounted to EUR 1,626,340.31, consisting of 16,263,403 full common shares, and 0.1 fraction of a share. Each full share entitles the holder or holders thereof to cast one vote. As a result, at the record date, the aggregate number of votes amounted to 16,263,403.

Thereupon the Chairman remarked that according to the attendance list, the holders of 4,324,844 shares are present or represented at the EGM, representing approximately 26.66% of the Company's issued share capital.

The Chairman did not receive proposals from shareholders with respect to the discussion of subjects other than those mentioned in the convening notice and on the agenda.

The Chairman then proceeded with the discussion of the EGM agenda items.

Agenda item 2: Appointment of Mr. Shawn Leland as a managing director

The Chairman noted that agenda item 2 concerns the proposal to appoint Dr. Leland as a member of the Management Board, for a term starting on the date of this EGM and ending at the end of the annual general meeting to be held in 2026.

The Chairman remarked that, subject to his appointment at this meeting, Dr. Leland would assume the role of Chief Executive Officer and chairman of the Management Board, and that Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024, would continue his position as Chief Medical Officer.

The Chairman provided the opportunity to discuss and ask questions and, after he established that there were no questions, he moved on to the voting on this matter. After the voting was completed, the Chairman established and announced that the EGM had adopted the proposal as set out in agenda item 2. Thereafter he moved on to the next agenda item.

Agenda item 3: Approval of an addendum to the Remuneration Policy for the Management Board in respect of Mr. Shawn Leland

The Chairman noted that agenda item 3 concerns the proposal to approve an addendum to the Remuneration Policy for the Management Board in respect of Dr. Shawn Leland. The Chairman noted that the additional terms under this addendum are intended to enable the Company to provide Dr. Leland market practice severance compensation, and he gave a brief explanation of the proposed addendum.

The Chairman provided the opportunity to discuss and ask questions and, after he established that there were no questions, he moved on to the voting on this matter. After the voting was completed, the Chairman established and announced that the EGM had adopted the proposal as set out in agenda item 3. Then the Chairman moved on to agenda item 4.

Agenda item 4: Any other business

The Chairman established that there were no further questions or any other business to be discussed at the EGM.

Agenda item 5: Closing

Then the Chairman thanked those attending the meeting and closed the EGM.

Dr. Thomas Hecht
Chairman

Reinier Kleipool
Secretary